⌘K
t
Tissue Regenix Group plc announced on 27 March 2025 that the European Patent Office granted it European patent EP4114476. This patent relates to the Company's dCELL® decellularisation technology for producing decellularisation tissue scaffold. This European patent adds to the Company's existing patents in the U.S. and U.K. for its dCELL technology.
| Date | 27 Mar 2025 |
| Time | 07:00:09 |
| Category | Miscellaneous |
| ID | 3920C |
Tissue Regenix Group plc
('Tissue Regenix', the 'Group' or the 'Company')
European patent granted
Further protecting the Company's proprietary decellularisation technology
Tissue Regenix (AIM: TRX), the regenerative medical devices company, announces it has been granted a European patent (EP4114476) by the European Patent Office for the Company's innovative decellularisation technology (dCELL®). The patent relates to the method for producing decellularisation tissue scaffold which is a foundation for Tissue Regenix's platform and plays a pivotal role in the development of its product range.
This development marks another significant milestone in the protection and commercial strength of the Company's intellectual property portfolio and reinforces the Company's commitment to innovation and leadership in the industry, as the Group expands its footprint in the global regenerative medicine and implantable device markets. This patent adds to those the Company already has granted in the U.S. and U.K. for its dCELL technology.
The Group's dCELL technology platform removes DNA and other cellular material from animal and human soft tissue, leaving an acellular tissue scaffold, which supports tissue growth and remodeling, is not rejected by the patient's body, and can then be used to repair diseased or damaged body parts.
Daniel Lee, CEO of Tissue Regenix, said: "Securing this patent is a significant achievement for the Company. It reflects the continuation of the strength of our innovation and the differentiated value we bring to the market. This protection is key as we continue to scale and build long-term value for patients, partners, and shareholders."
For more information, please contact:
|
Tissue Regenix Group plc |
|
|
|
Daniel Lee, Chief Executive Officer |
via Walbrook PR |
|
|
David Cocke, Chief Financial Officer |
|
|
|
|
|
|
|
Cavendish Capital Markets (Nominated Adviser and Broker) |
Tel: +44 (0) 20 7466 5000 |
|
|
Geoff Nash/Giles Balleny/Edward Whiley |
|
|
|
Nigel Birks - Life Science Specialist Sales |
|
|
|
Harriet Ward - ECM |
|
|
|
|
|
|
|
Walbrook PR (Financial PR and IR) |
Tel: +44 (0)20 7933 8780 |
|
|
Alice Woodings / Lianne Applegarth |
||
About Tissue Regenix (www.tissueregenix.com)
Tissue Regenix is a leading medical device company in regenerative medicine. The Company's patented decellularisation technology (dCELL®) removes DNA and other cellular material from animal and human soft tissue, leaving an acellular tissue scaffold that is not rejected by the patient's body and can be used to repair diseased or damaged body structures. Current applications address many crucial clinical needs in sports medicine, foot and ankle injuries and wound care.
In August 2017, Tissue Regenix acquired CellRight Technologies®. This biotech company specialises in regenerative medicine and is dedicated to developing high-quality, innovative tissue scaffolds to enhance healing opportunities in defects created by trauma and disease. CellRight's human tissue products may be used in spine, trauma, general orthopaedic, dental and ophthalmological surgical procedures.